12:00 AM
 | 
Aug 23, 2004
 |  BioCentury  |  Emerging Company Profile

Lectus: Accessory virtues

Ion channel modulators are widely marketed to treat cardiovascular and other indications. However, small molecule ion channel modulators historically are associated with side effects related to poor ion channel selectivity. Lectus Therapeutics Ltd. believes its Leveraged Enabling Proteomics Technology for Ion Channel Screening (LEPTICS) will allow it to overcome this problem by identifying small molecule compounds that bind more specific targets.

Lectus (Bristol, U.K.) is using the technology to discover compounds for urinary incontinence and other smooth muscle disorders, including angina and hypertension, while partnering other indications.

Ion channels are composed of many proteins. Some make up the pore-forming domain, through which ions such as potassium or sodium flow into a cell. Multiple accessory proteins interact with pore-forming domain proteins and can regulate ion channel activity.

Previous ion channel discovery work has focused on targeting pore-forming domains...

Read the full 675 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >